

(English Translation of Consolidated Financial Statements and Report Originally Issued in Chinese)

## **BIOTEQUE CORPORATION AND SUBSIDIARIES**

### **Consolidated Financial Statements**

#### **With Independent Auditors' Review Report For the Three Months Ended March 31, 2024 and 2023**

Address: 5F.-6, No.23, Sec.1. Chang-An E. Rd., Taipei City 104, Taiwan (R.O.C.)  
Telephone: +886-2-2571-0269

The independent auditors' review report and the accompanying consolidated financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors' review report and consolidated financial statements, the Chinese version shall prevail.

## Table of contents

Contents	Page
1. Cover Page	1
2. Table of Contents	2
3. Independent Auditors' Review Report	3
4. Consolidated Balance Sheets	4
5. Consolidated Statements of Comprehensive Income	5
6. Consolidated Statements of Changes in Equity	6
7. Consolidated Statements of Cash Flows	7
8. Notes to the Consolidated Financial Statements	
(1) Company history	8
(2) Approval date and procedures of the consolidated financial statements	8
(3) New standards, amendments and interpretations adopted	8~10
(4) Summary of material accounting policies	10~11
(5) Significant accounting assumptions and judgments, and major sources of estimation uncertainty	11
(6) Explanation of significant accounts	11~31
(7) Related-party transactions	31
(8) Assets Pledged as security	32
(9) Commitments and contingencies	32
(10) Losses Due to Major Disasters	32
(11) Subsequent Events	32
(12) Other	33
(13) Other disclosures	
(a) Information on significant transactions	34~36
(b) Information on investees	37
(c) Information on investment in mainland China	37
(d) Major shareholders	37
(14) Segment information	37



安侯建業聯合會計師事務所  
KPMG

台北市110615信義路5段7號68樓(台北101大樓)  
68F., TAIPEI 101 TOWER, No. 7, Sec. 5,  
Xinyi Road, Taipei City 110615, Taiwan (R.O.C.)

電話 Tel + 886 2 8101 6666  
傳真 Fax + 886 2 8101 6667  
網址 Web kpmg.com/tw

## Independent Auditors' Review Report

To the Board of Directors of Bioteque Corporation:

### Introduction

We have reviewed the accompanying consolidated balance sheets of Bioteque Corporation (the “Company”) and its subsidiaries (together referred to as the “Group”) as of March 31, 2024 and 2023, and the related consolidated statements of comprehensive income, changes in equity and cash flows for the three months ended March 31, 2024 and 2023, and notes to the consolidated financial statements, including a summary of significant accounting policies. Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, “Interim Financial Reporting” endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China. Our responsibility is to express a conclusion on the consolidated financial statements based on our reviews.

### Scope of Review

We conducted our reviews in accordance with the Standard on Review Engagements 2410, “Review of Financial Information Performed by the Independent Auditor of the Entity” of the Republic of China. A review of the consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing of the Republic of China and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

### Conclusion

Based on our reviews, nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of Bioteque Corporation and its subsidiaries as of March 31, 2024 and 2023, and of its consolidated financial performance and its consolidated cash flows for the three months ended March 31, 2024 and 2023 in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, “Interim Financial Reporting” endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.



The engagement partners on the reviews resulting in this independent auditors' review report are Huang, Ming-Hung and Tang, Chia-Chien.

KPMG

Taipei, Taiwan (Republic of China)

May 9, 2024

#### **Notes to Readers**

The accompanying consolidated financial statements are intended only to present the consolidated statement of financial position, financial performance and cash flows in accordance with the accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to review such consolidated financial statements are those generally accepted and applied in the Republic of China.

The independent auditors' review report and the accompanying consolidated financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors' review report and consolidated financial statements, the Chinese version shall prevail.

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

**BIOTEQUE CORPORATION AND SUBSIDIARIES****Consolidated Balance Sheets****March 31, 2024, December 31, 2023 and March 31, 2023****(Expressed in Thousands of New Taiwan Dollars)**

Assets		March 31, 2024		December 31, 2023		March 31, 2023		Liabilities and Equity		March 31, 2024		December 31, 2023		March 31, 2023	
		Amount	%	Amount	%	Amount	%			Amount	%	Amount	%	Amount	%
<b>Current assets :</b>								<b>Current liabilities:</b>							
1100	Cash and cash equivalents (note 6(a))	\$ 1,451,873	31	1,353,815	29	1,119,033	25	2130	Current contract liabilities (note 6(n))	\$ 41,385	1	38,082	1	39,356	1
	Current financial assets at fair value through profit or loss (note 6(b))	118,987	2	118,591	3	152,435	3	2150	Notes payable	214	-	211	-	487	-
1136	Current financial assets at amortized cost (note 6(c))	101,661	2	92,130	2	97,320	2	2170	Accounts payable	133,385	3	136,801	3	94,358	2
1150	Notes receivable, net (notes 6(d) and (n))	63,587	1	67,479	2	63,446	2	2209	Other payables (note 6(o))	137,428	3	136,019	3	122,026	3
1170	Accounts receivable, net (notes 6(d) and (n))	226,144	5	191,678	4	189,650	4	2213	Payable on machinery and equipment	64,841	1	103,930	2	108,969	3
130X	Inventories (note 6(e))	290,675	6	294,641	6	328,635	7	2216	Dividends payable (notes 6(l) and 7)	311,843	6	-	-	311,843	7
1476	Other current financial assets (note 8)	601	-	601	-	601	-	2230	Current tax liabilities	95,602	2	61,815	2	100,658	2
1479	Other current assets	31,569	1	32,283	1	29,863	1	2280	Current lease liabilities (note 6(i))	12,706	-	12,612	-	12,809	-
	<b>Total current assets</b>	<u>2,285,097</u>	<u>48</u>	<u>2,151,218</u>	<u>47</u>	<u>1,980,983</u>	<u>44</u>	2322	Long-term borrowings, current portion (note 6(h))	167,572	4	147,463	3	43,343	1
	<b>Non-current assets:</b>							2399	Other current liabilities	8,287	-	5,124	-	7,757	-
1600	Property, plant and equipment (notes 6(f), 8 and 9)	1,936,846	41	1,946,880	42	1,972,222	44		<b>Total current liabilities</b>	<u>973,263</u>	<u>20</u>	<u>642,057</u>	<u>14</u>	<u>841,606</u>	<u>19</u>
1755	Right-of-use assets (note 6(g))	349,797	7	345,181	7	355,379	8		<b>Non-Current liabilities:</b>						
1840	Deferred tax asset	6,520	-	6,520	-	2,774	-	2541	Long-term borrowings (note 6(h))	408,780	9	446,230	10	504,890	11
1915	Prepayments for business facilities (note 9)	163,474	4	161,839	4	190,086	4	2570	Deferred tax liabilities	45,445	1	45,445	1	37,940	1
1980	Other non-current financial assets	3,770	-	3,739	-	3,422	-	2580	Non-current lease liabilities (note 6(i))	291,219	6	288,225	6	297,627	7
1995	Other non-current assets	7,104	-	4,991	-	5,403	-	2640	Net defined benefit liability, non-current	8,284	-	8,284	-	12,905	-
	<b>Total non-current assets</b>	<u>2,467,511</u>	<u>52</u>	<u>2,469,150</u>	<u>53</u>	<u>2,529,286</u>	<u>56</u>		<b>Total non-current liabilities</b>	<u>753,728</u>	<u>16</u>	<u>788,184</u>	<u>17</u>	<u>853,362</u>	<u>19</u>
									<b>Total liabilities</b>	<u>1,726,991</u>	<u>36</u>	<u>1,430,241</u>	<u>31</u>	<u>1,694,968</u>	<u>38</u>
									<b>Equity attributable to owners of parent (note 6(l)):</b>						
								3100	Ordinary shares	692,983	14	692,983	15	692,983	15
								3200	Capital surplus	316,950	7	316,950	7	315,168	7
									Retained earnings:						
								3310	Legal reserve	511,268	11	511,268	11	462,155	10
								3320	Special reserve	1,102	-	1,102	-	50,620	1
								3350	Unappropriated retained earnings	1,470,984	31	1,657,141	36	1,299,018	29
										<u>1,983,354</u>	<u>42</u>	<u>2,169,511</u>	<u>47</u>	<u>1,811,793</u>	<u>40</u>
									Other equity:						
								3410	Exchange differences on translation of foreign financial statements	32,330	1	10,683	-	(4,643)	-
									<b>Total equity</b>	<u>3,025,617</u>	<u>64</u>	<u>3,190,127</u>	<u>69</u>	<u>2,815,301</u>	<u>62</u>
<b>Total assets</b>		<u>\$ 4,752,608</u>	<u>100</u>	<u>4,620,368</u>	<u>100</u>	<u>4,510,269</u>	<u>100</u>	<b>Total liabilities and equity</b>		<u>\$ 4,752,608</u>	<u>100</u>	<u>4,620,368</u>	<u>100</u>	<u>4,510,269</u>	<u>100</u>

See accompanying notes to consolidated financial statements.

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

**BIOTEQUE CORPORATION AND SUBSIDIARIES****Consolidated Statements of Comprehensive Income****For the three months ended March 31, 2024 and 2023****(Expressed in Thousands of New Taiwan Dollars, Except for Earnings Per Share)**

		<b>For the three months ended March 31</b>			
		<b>2024</b>		<b>2023</b>	
		<b>Amount</b>	<b>%</b>	<b>Amount</b>	<b>%</b>
4000	<b>Operating revenue (note 6(n))</b>	\$ 496,261	100	455,936	100
5000	<b>Operating costs (notes 6(e), (f), (g), (j) and 12)</b>	<u>291,052</u>	<u>59</u>	<u>276,328</u>	<u>61</u>
	<b>Gross profit from operations</b>	<u>205,209</u>	<u>41</u>	<u>179,608</u>	<u>39</u>
6000	<b>Operating expenses (notes 6(f), (g), (i), (j), (o), 7 and 12):</b>				
6100	Selling expenses	19,859	4	18,301	4
6200	Administrative expenses	24,663	5	22,660	5
6300	Research and development expenses	<u>20,191</u>	<u>4</u>	<u>14,974</u>	<u>3</u>
	<b>Total operating expenses</b>	<u>64,713</u>	<u>13</u>	<u>55,935</u>	<u>12</u>
6900	<b>Net operating income</b>	<u>140,496</u>	<u>28</u>	<u>123,673</u>	<u>27</u>
7000	<b>Non-operating income and expenses (notes 6(i) and (p)):</b>				
7100	Interest income	3,659	1	2,458	1
7010	Other income	983	-	611	-
7020	Other gains and losses	16,815	3	155	-
7050	Finance costs	<u>(2,526)</u>	<u>-</u>	<u>(2,648)</u>	<u>(1)</u>
	<b>Total non-operating income and expenses</b>	<u>18,931</u>	<u>4</u>	<u>576</u>	<u>-</u>
7900	<b>Profit before tax</b>	159,427	32	124,249	27
7951	<b>Less: Tax expenses (note 6(k))</b>	<u>33,741</u>	<u>7</u>	<u>25,550</u>	<u>5</u>
	<b>Profit</b>	<u>125,686</u>	<u>25</u>	<u>98,699</u>	<u>22</u>
8300	<b>Other comprehensive income (loss) (note 6(l)):</b>				
8360	<b>Components of other comprehensive income (loss) that will be reclassified to profit or loss:</b>				
8361	Exchange differences on translation	21,647	4	(3,541)	(1)
8399	Income tax related to components of other comprehensive income that will be reclassified to profit or loss	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
	<b>Total components of other comprehensive income (loss) that will be reclassified to profit or loss</b>	<u>21,647</u>	<u>4</u>	<u>(3,541)</u>	<u>(1)</u>
8300	<b>Other comprehensive income (loss), net</b>	<u>21,647</u>	<u>4</u>	<u>(3,541)</u>	<u>(1)</u>
	<b>Comprehensive income</b>	<u>\$ 147,333</u>	<u>29</u>	<u>95,158</u>	<u>21</u>
9750	<b>Basic earnings per share (note 6(m)) (Expressed in New Taiwan Dollars)</b>	<u>\$ 1.81</u>		<u>1.42</u>	
9850	<b>Diluted earnings per share (note 6(m)) (Expressed in New Taiwan Dollars)</b>	<u>\$ 1.81</u>		<u>1.42</u>	

See accompanying notes to consolidated financial statements.

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

**BIOTEQUE CORPORATION AND SUBSIDIARIES****Consolidated Statements of Changes in Equity****For the three months ended March 31, 2024 and 2023****(Expressed in Thousands of New Taiwan Dollars)**

	Attributable to owners of parent					Other equity Exchange differences on translation of foreign financial statements	Total equity
	Ordinary shares	Capital surplus	Legal reserve	Special reserve	Unappropriated retained earnings		
<b>Balance at January 1, 2023</b>	\$ 692,983	315,168	462,155	50,620	1,512,162	(1,102)	3,031,986
Net income for the three months ended March 31, 2023	-	-	-	-	98,699	-	98,699
Other comprehensive income for the three months ended March 31, 2023	-	-	-	-	-	(3,541)	(3,541)
Total comprehensive income for the three months ended March 31, 2023	-	-	-	-	98,699	(3,541)	95,158
Appropriation and distribution of retained earnings:							
Cash dividends	-	-	-	-	(311,843)	-	(311,843)
<b>Balance at March 31, 2023</b>	<b>\$ 692,983</b>	<b>315,168</b>	<b>462,155</b>	<b>50,620</b>	<b>1,299,018</b>	<b>(4,643)</b>	<b>2,815,301</b>
<b>Balance at January 1, 2024</b>	\$ 692,983	316,950	511,268	1,102	1,657,141	10,683	3,190,127
Net income for the three months ended March 31, 2024	-	-	-	-	125,686	-	125,686
Other comprehensive income for the three months ended March 31, 2024	-	-	-	-	-	21,647	21,647
Total comprehensive income for the three months ended March 31, 2024	-	-	-	-	125,686	21,647	147,333
Appropriation and distribution of retained earnings:							
Cash dividends	-	-	-	-	(311,843)	-	(311,843)
<b>Balance at March 31, 2024</b>	<b>\$ 692,983</b>	<b>316,950</b>	<b>511,268</b>	<b>1,102</b>	<b>1,470,984</b>	<b>32,330</b>	<b>3,025,617</b>

See accompanying notes to consolidated financial statements.

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

**BIOTEQUE CORPORATION AND SUBSIDIARIES****Consolidated Statements of Cash Flows****For the three months ended March 31, 2024 and 2023****(Expressed in Thousands of New Taiwan Dollars)**

	For the three months ended March 31	
	2024	2023
<b>Cash flows generated from (used in) operating activities:</b>		
Profit before tax	\$ 159,427	124,249
<b>Adjustments:</b>		
<b>Adjustments to reconcile profit (loss):</b>		
Depreciation expenses	38,024	37,549
Amortization expenses	891	791
Net gains on financial assets at fair value through profit or loss	(396)	(874)
Interest expenses	2,526	2,648
Net (gains) losses on financial assets at amortized cost	(3,820)	922
Interest income	(3,659)	(2,458)
Gains on lease modifications	-	(18)
Prepayments for business facilities transferred to expenses	-	264
Gains on disposal of property, plant and equipment	-	(18)
<b>Total adjustments to reconcile profit</b>	<b>33,566</b>	<b>38,806</b>
<b>Changes in operating assets:</b>		
Notes receivable	3,892	14,971
Accounts receivable	(34,466)	22,863
Inventories	3,966	3,078
Other current assets	3,421	5,443
<b>Total changes in operating assets</b>	<b>(23,187)</b>	<b>46,355</b>
<b>Changes in operating liabilities:</b>		
Current contract liabilities	3,303	(5,614)
Notes payable	3	310
Accounts payable	(3,416)	(40,951)
Other payables	1,443	(12,920)
Other current liabilities	3,163	(1,581)
Net defined benefit liability	-	(9)
<b>Total changes in operating liabilities</b>	<b>4,496</b>	<b>(60,765)</b>
<b>Total changes in operating assets and liabilities</b>	<b>(18,691)</b>	<b>(14,410)</b>
<b>Total adjustments</b>	<b>14,875</b>	<b>24,396</b>
Cash inflow generated from operations	174,302	148,645
Interest received	1,569	1,108
Income taxes paid	46	20
<b>Net cash flows generated from operating activities</b>	<b>175,917</b>	<b>149,773</b>
<b>Cash flows generated from (used in) investing activities:</b>		
Acquisition of financial assets at amortized cost	(99,931)	(91,330)
Proceeds from disposal of financial assets at amortized cost	94,130	91,188
Acquisition of property, plant and equipment	(4,593)	(7,651)
Proceeds from disposal of property, plant and equipment	-	80
Decrease (Increase) in other financial assets	(31)	25
Increase in other non-current assets	(3,004)	(547)
Increase in prepayments for business facilities	(6,133)	(8,656)
Decrease in payables on machinery and equipment	(39,089)	(16,486)
<b>Net cash used in investing activities</b>	<b>(58,651)</b>	<b>(33,377)</b>
<b>Cash flows generated from (used in) financing activities:</b>		
Repayments of long-term borrowings	(18,132)	(8,531)
Payment of lease liabilities	(3,251)	(3,451)
Interest paid	(2,564)	(2,591)
<b>Net cash used in financing activities</b>	<b>(23,947)</b>	<b>(14,573)</b>
<b>Effect on exchange rate changes on cash and cash equivalents</b>	<b>4,739</b>	<b>(86)</b>
<b>Net increase in cash and cash equivalents</b>	<b>98,058</b>	<b>101,737</b>
<b>Cash and cash equivalents at beginning of period</b>	<b>1,353,815</b>	<b>1,017,296</b>
<b>Cash and cash equivalents at end of period</b>	<b>\$ 1,451,873</b>	<b>1,119,033</b>

See accompanying notes to consolidated financial statements.



(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**

**Notes to the Consolidated Financial Statements**

**March 31, 2024 and 2023**

**(Expressed in Thousands of New Taiwan Dollars Except for Earnings Per Share Information and Unless Otherwise Specified)**

**(1) Company history**

Bioteque Corporation (“the Company”) was incorporation in November, 1991 in accordance with the Company Act and the other related laws and regulations.

The Company's stock was listed on Taipei Exchange on March 4, 2002.

The business operation of the Company and its subsidiaries (together referred to as “the Group”) are as follows:

- (a) Manufacturing, trading and selling of the medical cosumable.
- (b) Reinvestment and monopoly investment in securities business.

**(2) Approval date and procedures of the consolidated financial statements:**

The consolidated financial statements were authorized for issuance by the board of directors on May 9, 2024

**(3) New standards, amendments and interpretations adopted:**

- (a) The impact of the IFRS Accounting Standards endorsed by the Financial Supervisory Commission, R.O.C. which have already been adopted.

The Group has initially adopted the following new amendments, which do not have a significant impact on its consolidated financial statements, from January 1, 2024:

- Amendments to IAS 1 “Classification of Liabilities as Current or Non-current”
- Amendments to IAS 1 “Non-current Liabilities with Covenants”
- Amendments to IAS 7 and IFRS 7 “Supplier Finance Arrangements”
- Amendments to IFRS 16 “Lease Liability in a Sale and Leaseback”

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

- (b) The impact of IFRS Accounting Standards issued by IASB but not yet endorsed by the FSC

The following new and amended standards, which may be relevant to the Group, have been issued by the International Accounting Standards Board (IASB), but have yet to be endorsed by the FSC:

<b>Standards or Interpretations</b>	<b>Content of amendment</b>	<b>Effective date per IASB</b>
IFRS 18 “Presentation and Disclosure in Financial Statements”	<p>The new standard introduces three categories of income and expenses, two income statement subtotals and one single note on management performance measures. The three amendments, combined with enhanced guidance on how to disaggregate information, set the stage for better and more consistent information for users, and will affect all the entities.</p> <ul style="list-style-type: none"> <li>● A more structured income statement: under current standards, companies use different formats to present their results, making it difficult for investors to compare financial performance across companies. The new standard promotes a more structured income statement, introducing a newly defined ‘operating profit’ subtotal and a requirement for all income and expenses to be allocated between three new distinct categories based on a company’s main business activities.</li> <li>● Management performance measures (MPMs): the new standard introduces a definition for management performance measures, and requires companies to explain in a single note to the financial statements why the measure provides useful information, how it is calculated and reconcile it to an amount determined under IFRS Accounting Standards.</li> <li>● Greater disaggregation of information: the new standard includes enhanced guidance on how companies group information in the financial statements. This includes guidance on whether information is included in the primary financial statements or is further disaggregated in the notes.</li> </ul>	January 1, 2027

(Continued)

## BIOTEQUE CORPORATION AND SUBSIDIARIES

### Notes to the Consolidated Financial Statements

The Group is evaluating the impact on its consolidated financial position and consolidated financial performance upon the initial adoption of the abovementioned standards or interpretations. The results thereof will be disclosed when the Group completes its evaluation.

The Group does not expect the following other new and amended standards, which have yet to be endorsed by the FSC, to have a significant impact on its consolidated financial statements:

- Amendments to IFRS 10 and IAS 28 “Sale or Contribution of Assets Between an Investor and Its Associate or Joint Venture”
- IFRS 17 “Insurance Contracts” and amendments to IFRS 17 “Insurance Contracts”
- Amendments to IFRS 17 “Initial Application of IFRS 17 and IFRS 9 – Comparative Information”
- Amendments to IAS21 “Lack of Exchangeability”

#### (4) Summary of material accounting policies:

##### (a) Statement of compliance

These consolidated financial statements have been prepared in accordance with the preparation and guidelines of IAS 34 “Interim Financial Reporting” which are endorsed and issued into effect by FSC, and do not include all of the information required by the Regulations and International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations and SIC Interpretations endorsed and issued into effect by the FSC (hereinafter referred to IFRS endorsed by the FSC) for a complete set of the annual consolidated financial statements.

Except the following accounting policies mentioned below, the material accounting policies adopted in the consolidated financial statements are the same as those in the consolidated financial statement for the year ended December 31, 2023. For the related information, please refer to note 4 of the consolidated financial statements for the year ended December 31, 2023.

##### (b) Basis of consolidation

##### (i) List of subsidiaries in the consolidated financial statements:

Name of investor	Name of subsidiary	Principal activity	Shareholding			Note
			March 31, 2024	December 31, 2023	March 31, 2023	
The Company	BIOTEQUE MEDICAL CO., LTD.	Investment activities	- %	- %	100.00 %	Note 1
The Company	CHUNGTEX INVESTMENT CO., LTD.	Investment activities	100.00 %	100.00 %	100.00 %	Note 2
The Company	BIOTEQUE MEDICAL PHIL. INC.	Manufacturing and Trading of Medical equipment	100.00 %	100.00 %	100.00 %	
BIOTEQUE MEDICAL PHIL. INC.	BONTEQ MEDICAL DISTRIBUTION PHIL. INC.	Trading of Medical equipment	100.00 %	100.00 %	100.00 %	

Note 1: BIOTEQUE MEDICAL CO., LTD made remittance of share capital on December 25, 2023, and completed the liquidation process on February 12, 2024.

Note2 : The Company's Board of Directors resolved to dissolve and liquidate CHUNGTEX INVESTMENT CO., LTD. on 9 November 2023. As of March 31, 2024, the liquidation process was not completed.

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

(ii) List of subsidiaries which are not included in the consolidated financial statements: None.

(c) Income taxes

The income tax expenses have been prepared and disclosed in accordance with paragraph B12 of International Financial Reporting Standards 34, Interim Reporting.

Income tax expenses for the period are measured by multiplying together the pre-tax income for the interim reporting period and the management's best estimate of effective annual tax rate. This should be recognized fully as tax expense for the current period.

Temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and their respective tax bases shall be measured based on the tax rates that have been enacted or substantively enacted at the time of the asset or liability is recovered or settled, and be recognized directly in equity or other comprehensive income as tax expense.

(d) Employee benefits

The pension cost in the interim period was calculated and disclosed on a year-to-date basis by using the actuarially determined pension cost rate at the end of the prior fiscal year.

**(5) Significant accounting assumptions and judgments, and major sources of estimation uncertainty:**

The preparation of the consolidated financial statements in conformity with the Regulations and IFRSs (in accordance with IAS 34 "Interim Financial Reporting" and endorsed by the FSC) requires the management to make judgments, estimates and assumptions that affect the application of the accounting policies and the reported amount of assets, liabilities, income and expenses. Significant accounting estimates and assumptions made by the management may differ from the actual results and are continually evaluated and adjusted based on historical experience and other factors. The Group has considered the economic implications of climate change on critical accounting estimates and will continue evaluating the impact on its financial position and financial performance.

The preparation of the consolidated interim financial statements, estimates and underlying assumptions are reviewed on an ongoing basis which are in conformity with the consolidated financial statements for the year ended December 31, 2023.

**(6) Explanation of significant accounts:**

Except for the following disclosures, there is no significant difference as compared with those disclosed in the consolidated financial statements for the year ended December 31, 2023. Please refer to Note 6 of the 2023 annual consolidated financial statements.

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

## (a) Cash and cash equivalents

	<b>March 31, 2024</b>	<b>December 31, 2023</b>	<b>March 31, 2023</b>
Cash on hand	\$ 425	940	1,060
Cash in bank	1,451,448	1,352,875	1,117,973
Cash and cash equivalents in the consolidated statement of cash flows	<u>\$ 1,451,873</u>	<u>1,353,815</u>	<u>1,119,033</u>

## (b) Current financial assets at fair value through profit or loss

	<b>March 31, 2024</b>	<b>December 31, 2023</b>	<b>March 31, 2023</b>
<b>Mandatorily measured at fair value through profit or loss:</b>			
Non-derivative financial assets			
Money market funds and bond funds	\$ 118,987	118,591	140,643
Stock listed on domestic markets	-	-	11,792
Total	<u>\$ 118,987</u>	<u>118,591</u>	<u>152,435</u>

(i) For credit risk and market risk, please refer to note 6(q).

(ii) The financial assets of the Group were not collateralized.

## (c) Current financial assets measured at amortized cost

	<b>March 31, 2024</b>	<b>December 31, 2023</b>	<b>March 31, 2023</b>
Time deposits	<u>\$ 101,661</u>	<u>92,130</u>	<u>97,320</u>

The Group has assessed that these financial assets are held-to-maturity to collect contractual cash flows, which consist solely of payments of principal and interest on principal amount outstanding. Therefore, these investments were classified as financial assets measured at amortized cost.

(i) For the three months ended March 31, 2024 and 2023, the Group held domestic time deposits, with the weighted-average interest rates of 1.16%~5.45% and 1.19%~4.70%, respectively, which mature in April to June of 2024 and May to August of 2023, respectively.

(ii) For credit risk, please refer to note 6(q).

(iii) The financial assets of the Group were not collateralized.

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

## (d) Notes and accounts receivables

	<b>March 31, 2024</b>	<b>December 31, 2023</b>	<b>March 31, 2023</b>
Notes receivable	\$ 63,587	67,479	63,446
Accounts receivables	226,144	191,678	189,815
Less: loss allowance	-	-	(165)
	<u><u>\$ 289,731</u></u>	<u><u>259,157</u></u>	<u><u>253,096</u></u>

The Group applies the simplified approach to provide for its expected credit losses, i.e. the use of lifetime expected loss provision for all receivables. To measure the expected credit losses, receivables have been grouped based on shared credit risk characteristics and the days past due, as well as incorporated forward looking information. The loss allowances were determined as follows:

	<b>March 31, 2024</b>		
	<b>Gross carrying amount</b>	<b>Weighted- average loss rate</b>	<b>Loss allowance</b>
Current	\$ 272,539	-	-
1 to 30 days past due	17,186	-	-
31 to 60 days past due	-	-	-
61 to 90 days past due	6	-	-
91 to 120 days past due	-	-	-
121 to 150 days past due	-	-	-
151 to 180 days past due	-	0.88%	-
More than 181 days past due	-	100%	-
	<u><u>\$ 289,731</u></u>		<u><u>-</u></u>
	<b>December 31, 2023</b>		
	<b>Gross carrying amount</b>	<b>Weighted- average loss rate</b>	<b>Loss allowance</b>
Current	\$ 259,157	-	-
1 to 30 days past due	-	-	-
31 to 60 days past due	-	-	-
61 to 90 days past due	-	-	-
91 to 120 days past due	-	-	-
121 to 150 days past due	-	-	-
151 to 180 days past due	-	0.92%	-
More than 181 days past due	-	100%	-
	<u><u>\$ 259,157</u></u>		<u><u>-</u></u>

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

	<b>March 31, 2023</b>		
	<b>Gross carrying amount</b>	<b>Weighted- average loss rate</b>	<b>Loss allowance</b>
Current	\$ 245,581	-	-
1 to 30 days past due	7,515	-	-
31 to 60 days past due	-	-	-
61 to 90 days past due	-	-	-
91 to 120 days past due	-	-	-
121 to 150 days past due	-	4.23%	-
151 to 180 days past due	-	11.88%	-
More than 181 days past due	<u>165</u>	100%	<u>165</u>
	<u><u>\$ 253,261</u></u>		<u><u>165</u></u>

The movements in the allowance for notes, and accounts receivable were as follows:

	<b>Accounts receivable</b>
Balance at March 31, 2024 (same as beginning at January 1, 2024)	<u>\$ -</u>
Balance at March 31, 2023 (same as beginning at January 1, 2023)	<u><u>\$ 165</u></u>

The notes and accounts receivables of the Group were not collateralized.

For further credit risk information, please refer to note 6(q).

(e) Inventories

	<b>March 31, 2024</b>	<b>December 31, 2023</b>	<b>March 31, 2023</b>
Raw materials	\$ 140,168	132,346	172,200
Work in progress	55,276	64,786	66,204
Finished goods	66,434	73,799	66,540
Merchandise	9,539	12,161	9,467
Inventories in transit	<u>19,258</u>	<u>11,549</u>	<u>14,224</u>
	<u><u>\$ 290,675</u></u>	<u><u>294,641</u></u>	<u><u>328,635</u></u>

Except for cost of goods sold and inventories recognized as operating cost, the remaining gains or losses which were recognized as operating cost or deduction of operating cost were as follows:

	<b>For the three months ended March 31, 2024</b>	<b>For the three months ended March 31, 2023</b>
Gains on physical inventory	\$ (210)	(2)
Unallocated production overheads	<u>18,474</u>	<u>14,650</u>
	<u><u>\$ 18,264</u></u>	<u><u>14,648</u></u>

The inventories of the Group were not collateralized.

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

(f) Property, plant and equipment

The cost and accumulated depreciation of the property, plant and equipment of the Group for the three months ended March 31, 2024 and 2023 were as follows:

	<u>Land</u>	<u>Building and structures</u>	<u>Machinery and equipment</u>	<u>Transportation equipment</u>	<u>Office equipment</u>	<u>Other equipment</u>	<u>Construction in progress</u>	<u>Total</u>
Cost:								
Balance at January 1, 2024	\$ 91,834	1,819,008	994,554	11,385	22,295	241,428	57,981	3,238,485
Additions	-	-	936	1,022	1,205	1,430	-	4,593
Disposals	-	-	-	-	-	(1,354)	-	(1,354)
Reclassification (Note 1)	-	-	135	-	1,614	2,132	-	3,881
Effect on changes in foreign exchange rates	-	15,331	6,382	87	28	3,289	-	25,117
Balance at March 31, 2024	<u>\$ 91,834</u>	<u>1,834,339</u>	<u>1,002,007</u>	<u>12,494</u>	<u>25,142</u>	<u>246,925</u>	<u>57,981</u>	<u>3,270,722</u>
Balance at January 1, 2023	\$ 91,834	1,811,920	906,318	11,215	21,095	226,063	59,781	3,128,226
Additions	-	2,069	3,545	170	300	1,567	-	7,651
Disposals	-	-	(317)	-	-	(299)	-	(616)
Reclassification (Note 1)	-	4,200	22,975	-	-	3,547	(1,800)	28,922
Effect on changes in foreign exchange rates	-	(3,114)	(1,288)	(14)	(15)	(649)	-	(5,080)
Balance at March 31, 2023	<u>\$ 91,834</u>	<u>1,815,075</u>	<u>931,233</u>	<u>11,371</u>	<u>21,380</u>	<u>230,229</u>	<u>57,981</u>	<u>3,159,103</u>
Accumulated depreciation and impairment loss:								
Balance at January 1, 2024	\$ -	321,739	726,148	8,925	20,934	213,859	-	1,291,605
Depreciation	-	11,297	17,048	213	344	5,438	-	34,340
Disposals	-	-	-	-	-	(1,354)	-	(1,354)
Effect on changes in foreign exchange rates	-	2,535	3,819	69	25	2,837	-	9,285
Balance at March 31, 2024	<u>\$ -</u>	<u>335,571</u>	<u>747,015</u>	<u>9,207</u>	<u>21,303</u>	<u>220,780</u>	<u>-</u>	<u>1,333,876</u>
Balance at January 1, 2023	\$ -	276,791	658,497	8,077	19,872	192,148	-	1,155,385
Depreciation	-	11,167	16,272	211	208	5,791	-	33,649
Disposals	-	-	(317)	-	-	(237)	-	(554)
Effect on changes in foreign exchange rates	-	(436)	(640)	(14)	(14)	(495)	-	(1,599)
Balance at March 31, 2023	<u>\$ -</u>	<u>287,522</u>	<u>673,812</u>	<u>8,274</u>	<u>20,066</u>	<u>197,207</u>	<u>-</u>	<u>1,186,881</u>
Carrying amounts:								
Balance at January 1, 2024	<u>\$ 91,834</u>	<u>1,497,269</u>	<u>268,406</u>	<u>2,460</u>	<u>1,361</u>	<u>27,569</u>	<u>57,981</u>	<u>1,946,880</u>
Balance at March 31, 2024	<u>\$ 91,834</u>	<u>1,498,768</u>	<u>254,992</u>	<u>3,287</u>	<u>3,839</u>	<u>26,145</u>	<u>57,981</u>	<u>1,936,846</u>
Balance at January 1, 2023	<u>\$ 91,834</u>	<u>1,535,129</u>	<u>247,821</u>	<u>3,138</u>	<u>1,223</u>	<u>33,915</u>	<u>59,781</u>	<u>1,972,841</u>
Balance at March 31, 2023	<u>\$ 91,834</u>	<u>1,527,553</u>	<u>257,421</u>	<u>3,097</u>	<u>1,314</u>	<u>33,022</u>	<u>57,981</u>	<u>1,972,222</u>

(Note 1) Prepayments for business facilities were reclassified as property, plant and equipment.

As of March 31, 2024, December 31 and March 31, 2023, the property, plant and equipment of the Group had been pledged as collateral for borrowings; please refer to note 8.

(Continued)



**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

(g) Right-of-use assets

The Group leases land and buildings. Information about leases for which the Group has been a lessee is presented below:

	<u>Land</u>	<u>Buildings and structures</u>	<u>Total</u>
Cost:			
Balance at January 1, 2024	\$ 370,150	31,794	401,944
Additions	6,341	-	6,341
Effect on changes in foreign exchange rates	2,113	50	2,163
Balance at March 31, 2024	<u>\$ 378,604</u>	<u>31,844</u>	<u>410,448</u>
Balance at January 1, 2023	\$ 369,843	38,201	408,044
Disposals	-	(6,413)	(6,413)
Effect on changes in foreign exchange rates	(429)	30	(399)
Balance at March 31, 2023	<u>\$ 369,414</u>	<u>31,818</u>	<u>401,232</u>
Accumulated depreciation:			
Balance at January 1, 2024	\$ 31,521	25,242	56,763
Depreciation	2,327	1,357	3,684
Effect on changes in foreign exchange rates	156	48	204
Balance at March 31, 2024	<u>\$ 34,004</u>	<u>26,647</u>	<u>60,651</u>
Balance at January 1, 2023	\$ 22,407	24,625	47,032
Depreciation	2,276	1,624	3,900
Disposals	-	(5,077)	(5,077)
Effect on changes in foreign exchange rates	(24)	22	(2)
Balance at March 31, 2023	<u>\$ 24,659</u>	<u>21,194</u>	<u>45,853</u>
Carrying amount:			
Balance at January 1, 2024	<u>\$ 338,629</u>	<u>6,552</u>	<u>345,181</u>
Balance at March 31, 2024	<u>\$ 344,600</u>	<u>5,197</u>	<u>349,797</u>
Balance at January 1, 2023	<u>\$ 347,436</u>	<u>13,576</u>	<u>361,012</u>
Balance at March 31, 2023	<u>\$ 344,755</u>	<u>10,624</u>	<u>355,379</u>

(h) Short-term and long-term borrowings

(i) Short-term borrowings

	<u>March 31, 2024</u>	<u>December 31, 2023</u>	<u>March 31, 2023</u>
Unsecured bank loans	\$ -	-	-
Unused credit lines	<u>\$ 816,883</u>	<u>813,043</u>	<u>812,333</u>
Range of interest rate	-	<u>2%~6.39%</u>	-

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

(ii) Long-term borrowings

	<b>March 31, 2024</b>	<b>December 31, 2023</b>	<b>March 31, 2023</b>
Unsecured bank loans	\$ 576,352	593,693	548,233
Less: Current portion	<u>167,572</u>	<u>147,463</u>	<u>43,343</u>
Unsecured long-term borrowings	<u>\$ 408,780</u>	<u>446,230</u>	<u>504,890</u>
Unused credit lines	<u>\$ -</u>	<u>-</u>	<u>662,500</u>
Range of interest rate	<u>1.25%~6.1%</u>	<u>1.25%~6.1%</u>	<u>1.25%~6.1%</u>

Parts of the Group's long-term borrowings (included current portion) will be settled in foreign currency. The details of foreign long-term borrowings were as follows:

	<b>March 31, 2024</b>	<b>December 31, 2023</b>	<b>March 31, 2023</b>
USD (thousand dollars)	\$ <u>556</u>	<u>833</u>	<u>1,667</u>
Convert to NTD	<u>\$ 17,772</u>	<u>25,592</u>	<u>50,733</u>

As of March 31, 2024, the remaining balances of the long-term borrowings due were as follows:

<b>Period</b>	<b>Amount</b>
2024.04.01~2025.03.31	\$ 167,572
2025.04.01~2026.03.31	154,800
2026.04.01~2027.03.31	134,250
2027.04.01~2028.03.31	<u>119,730</u>
	<u>\$ 576,352</u>

For the collateral for borrowing, please refer to note 8.

(i) Lease liabilities

	<b>March 31, 2024</b>	<b>December 31, 2023</b>	<b>March 31, 2023</b>
Current	\$ <u>12,706</u>	<u>12,612</u>	<u>12,809</u>
Non-current	<u>\$ 291,219</u>	<u>288,225</u>	<u>297,627</u>

For the maturity analysis, please refer to note 6(q).

The amounts recognized in profit or loss were as follows:

	<b>For the three months ended March 31, 2024</b>	<b>For the three months ended March 31, 2023</b>
Interest on lease liabilities	\$ <u>464</u>	<u>482</u>
Expenses relating to leases of low-value assets	<u>\$ 15</u>	<u>15</u>

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

The amounts recognized in the statement of cash flows by the Group were as follows:

	<b>For the three months ended March 31, 2024</b>	<b>For the three months ended March 31, 2023</b>
Total cash outflow for leases	<u>\$ 3,730</u>	<u>3,948</u>

For the three months ended March 31, 2024 and March 31, 2023, the Group leases land, buildings and structures for its factory, office space, warehouse and parking lot. The leases run for a period of 2 to 20 years. Some leases include an option to renew the lease for an additional period of 2 to 20 years after the end of the contract term.

Some leases of equipment contain extension options exercisable. These leases are negotiated and monitored by local management, and accordingly, contain a wide range of different terms and conditions. The extension options held are exercisable only by the Group and not by the lessors. In which leasee is not reasonably certain to use an optional extended lease term, payments associated with the optional period are not included within lease liabilities.

(j) Employee benefits

(i) Defined benefit plans

Management believes that there was no material volatility of the market, no material reimbursement and settlement or other material one time events since prior fiscal year. As a result, the pension cost in the accompanying interim period was measured and disclosed according to the actuarial report as of December 31, 2023 and 2022.

The expenses recognized in profit or loss for the Group were as follows:

	<b>For the Three months ended March 31, 2024</b>	<b>For the Three months ended March 31, 2023</b>
Operating costs	\$ 77	77
Operating expenses	<u>192</u>	<u>1,377</u>
	<u>\$ 269</u>	<u>1,454</u>

(ii) Defined contribution plans

The pension costs incurred from the contributions to the Bureau of the Labor Insurance were as follow:

	<b>For the Three months ended March 31, 2024</b>	<b>For the Three months ended March 31, 2023</b>
Operating costs	\$ 1,424	1,374
Operating expenses	<u>781</u>	<u>746</u>
	<u>\$ 2,205</u>	<u>2,120</u>

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

- (iii) The Group's subsidiaries incorporated in the Philippine have a defined contribution plan, wherein a monthly contribution to an independent fund, administered by the government in accordance with the pension regulations in the Republic of the Philippines, are based on certain percentage of employees' monthly salaries and wages. The Group recognized the pension costs were as follows:

	<b>For the Three months ended March 31, 2024</b>	<b>For the Three months ended March 31, 2023</b>
Operating costs	\$ 37	33
Operating expenses	<u>20</u>	<u>12</u>
	<b><u>\$ 57</u></b>	<b><u>45</u></b>

- (k) Income taxes

The amounts of income tax were as follows:

	<b>For the Three months ended March 31, 2024</b>	<b>For the Three months ended March 31, 2023</b>
Current tax expenses	<b><u>\$ 33,741</u></b>	<b><u>25,550</u></b>

The Company's income tax returns for all years through 2022 were assessed by the tax authorities.

- (l) Capital and other equity

Except for the following disclosure, there was no significant change for capital and other equity for the periods from January 1 to March 31, 2024 and 2023. For the related information, please refer to note 6(l) of the consolidated financial statements for the year ended December 31, 2023.

As of March 31, 2024, December 31 2023 and March 31, 2023, the total number of authorized ordinary shares were both 120,000 thousand shares, with a par value of NT\$10 per share, of which 69,298 thousand shares was issued and outstanding. All issued shares were paid up upon issuance.

- (i) Capital surplus

Balances of capital surplus at the reporting date were as follows:

	<b>March 31, 2024</b>	<b>December 31, 2023</b>	<b>March 31, 2023</b>
Share capital	\$ 315,168	315,168	315,168
Donation from shareholders	<u>1,782</u>	<u>1,782</u>	<u>-</u>
	<b><u>\$ 316,950</u></b>	<b><u>316,950</u></b>	<b><u>315,168</u></b>

(Continued)

## **BIOTEQUE CORPORATION AND SUBSIDIARIES**

### **Notes to the Consolidated Financial Statements**

According to the R.O.C. Company Act, capital surplus can only be used to offset a deficit, and only the realized capital surplus can be used to increase the common stock or be distributed as cash dividends. The aforementioned realized capital surplus includes capital surplus resulting from premium on issuance of capital stock and earnings from donated assets received. According to the Regulations Governing the Offering and Issuance of Securities by Securities Issuers, capital increases by transferring capital surplus in excess of par value should not exceed 10% of the total common stock outstanding.

(ii) Retained earnings

The Company's Articles of Incorporation stipulate that 10% of the annual income or earnings, after deducting any accumulated deficit, shall be set aside as a legal reserve. When the balance of such legal reserve reaches an amount equal to the paid-in capital, the appropriation to legal reserves is discontinued. If there are surplus profits remaining, at least 20% shall be allocated for distribution of shareholder dividends. The Board of Directors drafts a dividend distribution proposal and submits it to the shareholders meeting for resolution, in which cash dividends should make up at least 20% or more.

The Company should distribute dividends, bonuses, and capital reserves with cash. Distribution of dividends shall be undertaken by a resolution adopted by a majority vote at a Board meeting attended by at least two-thirds of the total number of directors, and a report of such distribution shall be submitted to the shareholders' meeting.

Because the industry the Company is involved in is undergoing a steady period of growth, the conditions, amount, and type of dividends mentioned in the preceding articles can be adjusted in response to the shifting market conditions and industry changes. In the mean time, the Company should consider the sustainable development and capital needs.

1) Legal reserve

When a company incurs no loss, it may, pursuant to a resolution by a shareholders' meeting, distribute its legal reserve by issuing new shares or by distributing cash, and only the portion of legal reserve which exceeds 25% of capital may be distributed.

2) Special reserve

In accordance with Ruling No. 1010012865 issued by the FSC on April 6, 2012, a portion of current-period earnings and undistributed prior-period earnings shall be reclassified as special earnings reserve during earnings distribution. The amount to be reclassified should equal the current-period total net reduction of other shareholders' equity. Similarly, a portion of undistributed prior-period earnings shall be reclassified as special earnings reserve (which does not qualify for earnings distribution) to account for cumulative changes to other shareholders' equity pertaining to prior periods. The amounts of subsequent reversals pertaining to the net reduction of other shareholders' equity shall qualify for additional distributions.

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

3) Earnings distribution

On March 6, 2024, the board of directors' meeting resolved to distribute the 2023 earnings. On March 9, 2023, the board of directors' meeting resolved to distribute the 2022 earnings. These earnings were appropriated as follows:

	2023		2022	
	Amount per share (NTD)	Amount	Amount per share (NTD)	Amount
Dividends distributed to ordinary shareholders:				
Cash	\$ 4.50	\$ <u>311,843</u>	4.50	<u>311,843</u>

(iii) Other equity

	<b>Exchange differences on translation of foreign financial statements</b>
Balance at January 1, 2024	\$ 10,683
Exchange differences on foreign operations	21,647
Balance at March 31, 2024	\$ <u>32,330</u>
	<b>Exchange differences on translation of foreign financial statements</b>
Balance at January 1, 2023	\$ (1,102)
Exchange differences on foreign operations	(3,541)
Balance at March 31, 2023	\$ <u>(4,643)</u>

(m) Earnings per share

The Company's earnings per share were calculated as follows:

(i) Basic earnings per share

	<b>For the Three months ended March 31, 2024</b>	<b>For the three months ended March 31, 2023</b>
Profit attributable to ordinary shareholders of the Company	\$ <u>125,686</u>	<u>98,699</u>
Weighted-average number of ordinary shares (in thousand shares)	<u>69,298</u>	<u>69,298</u>
Basic earnings per share (express in New Taiwan Dollars)	\$ <u>1.81</u>	<u>1.42</u>

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

(ii) Diluted earnings per share

	<b>For the three months ended March 31, 2024</b>	<b>For the three months ended March 31, 2023</b>
Profit attributable to ordinary shareholders of the Company	\$ <u>125,686</u>	<u>98,699</u>
Weighted-average number of ordinary shares (basic)(in thousand shares)	69,298	69,298
Effect on employee remuneration (in thousand shares)	<u>252</u>	<u>267</u>
Weighted-average number of ordinary shares (diluted) (in thousand shares)	<u>69,550</u>	<u>69,565</u>
Diluted earnings per share (express in New Taiwan Dollars)	\$ <u>1.81</u>	<u>1.42</u>

(n) Revenue from contracts with customers

(i) Disaggregation of revenue

	<b>For the Three months ended March 31, 2024</b>	<b>For the Three months ended March 31, 2023</b>
Primary geographical markets:		
Asia	\$ 221,522	232,309
South America	41,827	38,503
North America	64,316	59,881
Others	<u>168,596</u>	<u>125,243</u>
Total	\$ <u>496,261</u>	<u>455,936</u>
Major products service lines:		
Manufacturing, trading and selling of medical consumable	\$ <u>496,261</u>	<u>455,936</u>

(ii) Contract balances

	<b>March 31, 2024</b>	<b>December 31, 2023</b>	<b>March 31, 2023</b>
Notes and accounts receivable	\$ 289,731	259,157	253,261
Less: allowance for impairment	<u>-</u>	<u>-</u>	<u>(165)</u>
Total	\$ <u>289,731</u>	<u>259,157</u>	<u>253,096</u>
	<b>March 31, 2024</b>	<b>December 31, 2023</b>	<b>March 31, 2023</b>
Current contract liabilities	\$ <u>41,385</u>	<u>38,082</u>	<u>39,356</u>

For details on accounts receivable and allowance for impairment, please refer to note 6(d).

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

The amount of revenue recognized for the three months ended March 31, 2024 and 2023 that was included in the contract liability balance at the beginning of the period were \$26,922 and \$39,292, respectively.

The major change in the balance of contract assets and liabilities is the difference between the time frame in the performance obligation to be satisfied and the payment to be received.

(o) Remuneration to employees and directors

According to the Article of Association, once the Company has annual profit, it should appropriate no less than 5% of the profit to its employees and 1.6% or less to its directors.

The Company's estimated remuneration is as follows:

	<b>For the Three months ended March 31, 2024</b>	<b>For the Three months ended March 31, 2023</b>
Employees' remuneration	\$ 8,412	6,605
Directors' remuneration	<u>2,692</u>	<u>2,257</u>
	<b><u>\$ 11,104</u></b>	<b><u>8,862</u></b>

The amount of employees' remuneration, and directors' remuneration were estimated based on profit before tax, net of the amount of the remuneration, and multiplied by the rule of Company's Article of Association. The above remuneration were included in the operating expenses of the three months ended March 31, 2024 and 2023. The differences between the actual distributed amounts as determined by the Board of Directors and those recognized in the financial statements, if any, shall be accounted for as changes in accounting estimates and recognized in profit or loss in the following year.

The remunerations to employees amounted to \$30,179 and \$32,969, respectively, for the years ended December 31, 2023 and 2022. The remunerations to directors amounted to \$9,657 and \$10,550, respectively, for the years ended December 31, 2023 and 2022.

There was no difference between the actual distributed amounts as determined by the Board of Directors and those recognized in the financial statement for the years of 2023 and 2022.

The related information mentioned above can be found on websites such as the Market Observation Post System.

(Continued)



**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

(p) Non-operating income and expenses

(i) Interest income

	<b>For the Three months ended March 31, 2024</b>	<b>For the Three months ended March 31, 2023</b>
Interest income:		
Interest income from deposit	\$ 5	5
Interest income from bank deposit	3,455	2,453
Other	<u>199</u>	<u>-</u>
	<b><u>\$ 3,659</u></b>	<b><u>2,458</u></b>

(ii) Other income

	<b>For the Three months ended March 31, 2024</b>	<b>For the Three months ended March 31, 2023</b>
Subsidy revenue	\$ -	177
Compensation income	125	31
Others	<u>858</u>	<u>403</u>
	<b><u>\$ 983</u></b>	<b><u>611</u></b>

(iii) Other gains and losses

	<b>For the Three months ended March 31, 2024</b>	<b>For the Three months ended March 31, 2023</b>
Foreign exchange gains	\$ 12,661	240
Gains on financial assets at fair value through profit or loss	396	874
Gains (losses) on financial assets at amortized cost	3,820	(922)
Others	<u>(62)</u>	<u>(37)</u>
	<b><u>\$ 16,815</u></b>	<b><u>155</u></b>

(iv) Finance costs

	<b>For the Three months ended March 31, 2024</b>	<b>For the Three months ended March 31, 2023</b>
Interest expense on bank borrowings	\$ 2,062	2,166
Interest expense on lease liabilities	<u>464</u>	<u>482</u>
	<b><u>\$ 2,526</u></b>	<b><u>2,648</u></b>

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

(q) Financial instruments

Except for the content mentioned below, there was no significant change in the fair value of the Group's financial instruments and degree of exposure to credit risk, liquidity risk and market risk arising from financial instruments. For the related information please refer to note 6(q) of the consolidated financial statements for the year ended December 31, 2023. Regarding how the financial instruments are considered to have low credit risk, please refer to note 4(g) of the consolidated financial statements for the year ended December 31, 2023.

(i) Credit risk

1) Credit risk exposure

The carrying amount of financial assets represents the maximum amount exposed to credit risk.

As of March 31, 2024, December 31, 2023 and March 31, 2023, 30%, 36% and 42%, of the Group's notes and accounts receivable were two, two and three customers respectively.

2) Receivables securities

For credit risk exposure of notes and trade receivables, please refer to note 6(d).

Other financial assets at amortized costs Mainly time deposits.

As of these financial assets are considered to have low risk, and thus, the impairment provision recognized during the period was limited to 12 months expected losses.

The correlation credit risk , please refer to note 6(c).

(ii) Liquidity risk

The following table shows the contractual maturities of financial liabilities, including estimated interest payments and excluding the impact of netting agreements.

	<u>Carrying amount</u>	<u>Contractual cash flows</u>	<u>within 1 year</u>	<u>1-2 years</u>	<u>2-5 years</u>	<u>Over 5 years</u>
<b>March 31, 2024</b>						
Non-derivative financial liabilities						
Notes payable	\$ 214	214	214	-	-	-
Accounts payable	133,385	133,385	133,385	-	-	-
Other payables	137,428	137,428	137,428	-	-	-
Payables on machinery and equipment	64,841	64,841	64,841	-	-	-
Dividends payable	311,843	311,843	311,843	-	-	-
Long-term borrowings (including current portion)	576,352	582,859	170,600	156,722	255,537	-
Lease liabilities (current and non-current)	303,925	337,199	14,505	9,386	27,850	285,458
	<u>\$ 1,527,988</u>	<u>1,567,769</u>	<u>832,816</u>	<u>166,108</u>	<u>283,387</u>	<u>285,458</u>

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

	<u>Carrying amount</u>	<u>Contractual cash flows</u>	<u>within 1 year</u>	<u>1-2 years</u>	<u>2-5 years</u>	<u>Over 5 years</u>
<b>December 31, 2023</b>						
Non-derivative financial liabilities						
Notes payable	\$ 211	211	211	-	-	-
Accounts payable	136,801	136,801	136,801	-	-	-
Other payables	136,019	136,019	136,019	-	-	-
Payables on machinery and equipment	103,930	103,930	103,930	-	-	-
Long-term borrowings (including current portion)	593,693	600,729	150,408	151,895	298,426	-
Lease liabilities (current and non-current)	<u>300,837</u>	<u>333,865</u>	<u>14,397</u>	<u>10,495</u>	<u>27,262</u>	<u>281,711</u>
	<u>\$ 1,271,491</u>	<u>1,311,555</u>	<u>541,766</u>	<u>162,390</u>	<u>325,688</u>	<u>281,711</u>
<b>March 31, 2023</b>						
Non-derivative financial liabilities						
Notes payable	\$ 487	487	487	-	-	-
Accounts payable	94,358	94,358	94,358	-	-	-
Other payables	122,026	122,026	122,026	-	-	-
Payables on machinery and equipment	108,969	108,969	108,969	-	-	-
Dividends payable	311,843	311,843	311,843	-	-	-
Long-term borrowings (including current portion)	548,233	556,460	45,562	134,066	376,832	-
Lease liabilities (current and non-current)	<u>310,436</u>	<u>344,867</u>	<u>14,667</u>	<u>14,308</u>	<u>27,365</u>	<u>288,527</u>
	<u>\$ 1,496,352</u>	<u>1,539,010</u>	<u>697,912</u>	<u>148,374</u>	<u>404,197</u>	<u>288,527</u>

The Group does not expect the cash flows included in the maturity analysis to occur significantly earlier or at significantly different amount.

(iii) Market risk

1) Currency risk

The Group's significant exposure to foreign currency risk was as follows:

	<u>March 31, 2024</u>			<u>December 31, 2023</u>			<u>March 31, 2023</u>			
	<u>Foreign currency (in thousands)</u>	<u>Exchange rate</u>	<u>NTD</u>	<u>Foreign currency (in thousands)</u>	<u>Exchange rate</u>	<u>NTD</u>	<u>Foreign currency (in thousands)</u>	<u>Exchange rate</u>	<u>NTD</u>	
<b>Financial assets</b>										
<u>Monetary items</u>										
USD	\$	10,481	31.99	335,298	14,453	30.71	443,842	13,927	30.44	423,934
EUR		567	34.18	19,386	509	33.92	17,256	572	33.15	18,961
JPY		93,471	0.2100	19,629	24,898	0.2163	5,385	44,993	0.2288	10,292
PHP		149,147	0.5691	84,885	152,229	0.5521	84,045	201,345	0.5603	112,809
CNY		17,050	4.370	74,508	17,981	4.415	79,387	14,807	4.430	65,596
<u>Investments accounted for using equity method</u>										
USD		15,353	31.99	491,149	15,292	30.71	469,626	15,566	30.44	473,819
PHP		94,934	0.5691	54,030	85,118	0.5521	46,993	68,380	0.5603	38,312

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

	March 31, 2024			December 31, 2023			March 31, 2023		
	Foreign currency (in thousands)	Exchange rate	NTD	Foreign currency (in thousands)	Exchange rate	NTD	Foreign currency (in thousands)	Exchange rate	NTD
Financial liabilities									
Monetary items									
USD	1,843	31.99	58,955	2,416	30.71	74,182	2,124	30.44	64,646
EUR	233	34.18	7,970	233	33.92	7,917	245	33.15	8,132
JPY	44,148	0.2100	9,271	54,385	0.2163	11,763	45,457	0.2288	10,398
PHP	11,878	0.5691	6,760	9,463	0.5521	5,225	10,549	0.5603	5,911

The Group's exposure to foreign currency risk arise from the translation of the foreign currency exchange gains and losses on cash and cash equivalents, accounts receivables, other receivables, accounts payable, other payables and payables on machinery and equipment that are denominated in foreign currency.

A depreciation (appreciation) of 1% of the NTD against the foreign currency for the three months ended March 31, 2024 and 2023, would have increased (decreased), the net profit before tax by \$4,508 and \$5,425, respectively. The analysis is performed on the same basis for 2023.

Since the Group has many kinds of functional currency, the information on foreign exchange gain (loss) on monetary items is disclosed by total amount. For the three months ended March 31, 2024 and 2023, foreign exchange gains(losses) (including realized and unrealized portions) amounted to \$12,661 and \$240, respectively.

2) Interest rate analysis

Please refer to the notes on liquidity risk management and interest rate exposure of the Group's financial assets and liabilities.

The following sensitivity analysis is based on the exposure to the interest rate risk of non-derivative financial instruments on the reporting date. Regarding assets with variable interest rates, the analysis is based on the assumption that the amount of assets outstanding at the reporting date was outstanding throughout the year. The rate of change is expressed as the interest rate increases or decreases by 1% when reporting to management internally, which also represents the Group management's assessment of the reasonably possible interest rate change.

If the interest rate had increased / decreased by 1%, the Group's net profit before tax would have decreased / increased by \$1,441 and \$1,371 for the three months ended March 31, 2024 and 2023, respectively, with all other variable factors remain constant. This is mainly due to the Group's borrowing at floating rates.

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

3) Other market price risk

For the three months ended March 31, 2024 and 2023, the sensitivity analyzes for the changes in the securities price at the reporting date were performed using the same basis for the profit and loss as illustrated below:

Prices of securities at the reporting date	For the three months ended March 31			
	2024		2023	
	Other comprehensive income before tax	Net profit before tax	Other comprehensive income before tax	Net profit before tax
Increasing 1%	\$ -	1,190	-	1,524
Decreasing 1%	\$ -	(1,190)	-	(1,524)

(iv) Fair value of financial instruments

1) Fair value hierarchy

The carrying amount and fair value of the Group's financial assets and liabilities, including the information on fair value hierarchy were as follows, however, except as described in the following paragraphs, for financial instruments not measured at fair value whose carrying amount is reasonably close to the fair value, and lease liabilities, disclosure of fair value information is not required:

	March 31, 2024				
	Book value	Fair value			Total
		Level 1	Level 2	Level 3	
Financial assets at fair value through profit or loss					
Non-derivative financial assets mandatorily measured at fair value through profit or loss	\$ 118,987	118,987	-	-	118,987
Financial assets measured at amortized cost					
Cash and cash equivalents	1,451,873	-	-	-	-
Financial assets measured at amortized cost	101,661	-	-	-	-
Receivables	289,731	-	-	-	-
Other financial assets	4,371	-	-	-	-
Subtotal	1,847,636	-	-	-	-
Total	\$ 1,966,623	118,987	-	-	118,987
Financial liabilities measured at amortized cost					
Notes and accounts payable	\$ 133,599	-	-	-	-
Other payables	137,428	-	-	-	-
Payables on machinery and equipment	64,841	-	-	-	-
Dividends payable	311,843	-	-	-	-
Long-term borrowings (including current portion)	576,352	-	-	-	-
Lease liabilities (current and non-current)	303,925	-	-	-	-
Total	\$ 1,527,988	-	-	-	-

(Continued)



**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

Quoted market prices may not be indicative of the fair value of an instrument if the activity in the market is infrequent, the market is not well-established, only small volumes are traded, or bid-ask spreads are very wide. Determining whether a market is active involves judgment.

When the financial instruments of the Group are traded in an active market, its fair value is illustrated by the category and nature as follows:

The fair value of listed stocks and funds traded in an active market is based on the market quoted price.

Measurements of fair value of financial instruments without an active market are based on valuation technique or quoted price from a competitor. Fair value, measured by using valuation technique that can be extrapolated from either similar financial instruments or discounted cash flow method or other valuation techniques, including models, is calculated based on available market data at the reporting date.

3) Categories and fair values of financial instruments

The Group strives to use market observable inputs when measuring assets and liabilities. Different levels of the fair value hierarchy to be used in determining the fair value of financial instruments are as follows:

- a) Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.
- b) Level 2: inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- c) Level 3: inputs for the assets or liability that are not based on observable market data (unobservable inputs).

For the three months ended March 31, 2024 and 2023, there were no change on the fair value hierarchy of financial asset.

(r) Financial risk management

There were no significant changes in the Group's financial risk management and policies as disclosed in note 6(r) of the consolidated financial statements for the year ended December 31, 2023.

(s) Capital management

Management believes that the objectives, policies and processes of capital management of the Group has been applied consistently with those described in the consolidated financial statements for the year ended December 31, 2023. Also, management believes that there were no significant changes in the Group's capital management information as disclosed for the year ended December 31, 2023. Please refer to Note 6(s) of the consolidated financial statements for the year ended December 31, 2023 for further details.

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

(t) Investing and financing activities not affecting current cash flow

The Group's financial activities which did not affect the current cash flow for the three months ended March 31, 2024 and March 31, 2023 were as follows:

(i) For right-of-use assets under leases, please refer to note 6(g).

(ii) Reconciliation of liabilities arising from financial activities was as follows:

	January 1, 2024	Cash flows	Non-cash changes		March 31, 2024
			Foreign exchange movement	Other	
Long-term borrowings (including current portion)	\$ 593,693	(18,132)	791	-	576,352
Lease liabilities (current and non-current)	300,837	(3,251)	2	6,337	303,925
Total liabilities from financial activities	<u>\$ 894,530</u>	<u>(21,383)</u>	<u>793</u>	<u>6,337</u>	<u>880,277</u>

  

	January 1, 2023	Cash flows	Non-cash changes		March 31, 2023
			Foreign exchange movement	Other	
Long-term borrowings (including current portion)	\$ 557,194	(8,531)	(430)	-	548,233
Lease liabilities (current and non-current)	315,234	(3,451)	7	(1,354)	310,436
Total liabilities from financial activities	<u>\$ 872,428</u>	<u>(11,982)</u>	<u>(423)</u>	<u>(1,354)</u>	<u>858,669</u>

**(7) Related-party transactions:**

(a) Names and relationship with the Group

Name	Relationship with the Group
Ke Yue Co., Ltd.	The entity with significant influence over the Group
Yi de Co., Ltd.	Other related party
Yi sheng Co., Ltd.	Other related party

(b) Significant transactions with related parties:

Dividends payable to corporate shareholders as of March 31, 2024, December 31, 2023 and March 31, 2023, were \$52,340, \$0 and \$46,044, respectively, and were recorded under dividends payable.

(c) Key management personnel compensation

Key management personnel compensation was comprised as below:

	For the Three months ended March 31, 2024	For the Three months ended March 31, 2023
Short-term employee benefits	\$ 6,635	5,755
Post-employment benefits	174	1,359
	<u>\$ 6,809</u>	<u>7,114</u>

(Continued)



**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

**(8) Assets Pledged as security:**

<u>Pledged assets</u>	<u>Pledged to secure</u>	<u>March 31, 2024</u>	<u>December 31, 2023</u>	<u>March 31, 2023</u>
Other current financial assets:				
Restricted bank deposit	Purchase guarantee	\$ 601	601	601
Property, plant and equipment:				
Land	Credit of short-term borrowings	91,834	91,834	91,834
Buildings and structures	Credit of short-term borrowings	<u>155,106</u>	<u>157,174</u>	<u>163,379</u>
		<u>\$ 247,541</u>	<u>249,609</u>	<u>255,814</u>

**(9) Commitments and contingencies:**

## (a) Contingencies

In prior years, the Group entered into the license agreement which has expired with a supplier. On July 5, 2018, the supplier filed a complaint which has not completed accusing the Group. The Group assess there is no significant impact on its financial statements.

## (b) Notes issued as guarantee

	<u>March 31, 2024</u>	<u>December 31, 2023</u>	<u>March 31, 2023</u>
Bank borrowings and lease guarantee	<u>\$ 2,065,945</u>	<u>2,058,905</u>	<u>2,057,420</u>

## (c) The agreements for expansion of the factory and purchases of machinery and equipment

	<u>March 31, 2024</u>	<u>December 31, 2023</u>	<u>March 31, 2023</u>
Total contract price	<u>\$ 231,082</u>	<u>236,831</u>	<u>461,238</u>
Paid amount	<u>\$ 201,663</u>	<u>210,804</u>	<u>234,743</u>

**(10) Losses Due to Major Disasters: None****(11) Subsequent Events: None**

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

**(12) Other:**

(a) A summary of employee benefits, depreciation, and amortization, by function, is as follows:

By item	For the Three months ended March 31, 2024			For the Three months ended March 31, 2023		
	Cost of sales	Operating expenses	Total	Cost of sales	Operating expenses	Total
Employee benefits						
Salary	53,617	27,196	80,813	49,083	25,061	74,144
Labor and health insurance	4,200	1,896	6,096	4,211	2,167	6,378
Pension	1,538	993	2,531	1,484	2,135	3,619
Remuneration of directors	-	2,692	2,692	-	2,257	2,257
Others	2,909	1,175	4,084	2,189	875	3,064
Depreciation	35,307	2,717	38,024	35,023	2,526	37,549
Amortization	357	534	891	270	521	791

(b) Seasonality of operations

The Group's operations were not affected by seasonality or cyclical factors.

(Continued)

## BIOTEQUE CORPORATION AND SUBSIDIARIES

### Notes to the Consolidated Financial Statements

#### (13) Other disclosures:

##### (a) Information on significant transactions:

The followings is the information on the Group's significant transactions required by the "Regulations Governing the Preparation of Financial Reports by Securities Issuers" for the three months ended March 31, 2024:

##### (i) Loans to other parties:

(In thousands of NTD and USD)

Number	Name of lender	Name of borrower	Account name	Related party	Highest balance of financing to other parties during the period (Note 3)	Ending balance (Note 3)	Actual usage amount during the period (Note 4)	Range of interest rates during the period	Purposes of fund financing for the borrower (Note 1)	Transaction amount for business between two parties	Reasons for short-term financing	Allowance for bad debt	Collateral		Individual funding loan limits (Note 2)	Maximum limit of fund financing (Note 2)
													Item	Value		
0	The Company	BIOTEQUE MEDICAL PHIL. INC.	Accounts receivable from related parties	Yes	159,950 (USD 5,000)	159,950 (USD 5,000)	95,970 (USD 3,000)	3.00%	2	-	Working Capital	-	None	-	3,025,617 (Note 2)	3,025,617 (Note 2)

Note 1: Purposes of lending were as follows:

1. Business relationship
2. Short-term financing

Note 2: For entities in which the Company, directly or indirectly, owned 100% of their shares, the amount available for financing shall not exceed the net worth of the borrower.

Note 3: The maximum balance for the period and ending balance represent the amounts approved by the Board of Directors.

Note 4: The amounts of the transaction and the ending balance had been offset in the consolidated financial statements.

##### (ii) Guarantees and endorsements for other parties:

(In thousands of NTD and USD)

Number	Name of guarantor	Counterparty of guarantee and endorsement		Limitation on amount of guarantees and endorsements for a specific enterprise (Note 2)	Highest balance of guarantees and endorsements during the period	Balance of guarantees and endorsements as of reporting date	Actual usage amount	Property pledged for guarantees and endorsements (Amount)	Ratio of accumulated amounts of guarantees and endorsements to net worth of the latest financial statements	Maximum amount for guarantees and endorsements (Note 1)	Parent company endorsements/ guarantees to third parties on behalf of subsidiary	Subsidiary endorsements/ guarantees to third parties on behalf of parent company	Endorsements/ guarantees to third parties on behalf of companies in Mainland China
		Name	Relationship with the Company (Note 3)										
0	The Company	BIOTEQUE MEDICAL PHIL. INC.	2	207,894	175,945 (USD 5,500)	175,945 (USD 5,500)	17,772 (USD 556)	-	5.82 %	339,561	Y	N	N

Note 1: The total amount for the guarantees and endorsements provided by the Company to external entities shall not exceed 49% of the Company's shares. The total amount for the guarantees and endorsements provided by the Company and its subsidiaries to external entities shall not exceed 49% of the Company's net worth.

Note 2: The total amount for the guarantees and endorsements provided by the Company to any individual entity shall not exceed 30% of the Company's shares. The total amount for the guarantees and endorsements provided by the Company and its subsidiaries to any individual entity shall not exceed 30% of the Company's net worth.

Note 3: Relationship with the Company

1. Ordinary business relationship.
2. An entity, directly and indirectly, owned more than 50% voting shares of a guarantor.
3. A guarantor, directly and indirectly, owned more than 50% voting shares of an entity.
4. An entity, directly and indirectly, owned more than 90% voting shares of a guarantor.
5. Fulfillment of contractual obligations by providing mutual endorsements and guarantees for peer or joint builders in order to undertake a construction project.
6. An entity that is guaranteed and endorsed by all capital contributing shareholders in proportion to their shareholding percentages.
7. Peer engaged in the escrow of the sales contract on pre-sale house under the Consumer Protection Act.

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

(iii) Information regarding securities held at the reporting date (subsidiaries, associates and joint ventures not included):

(In thousands of NTD and shares)

Name of holder	Category and name of security	Relationship with company	Account title	Ending balance				Remark
				Shares/Units (in thousands)	Carrying value	Percentage of ownership (%)	Fair value	
The Company	Capital Money Market Fund	None	Current financial assets at fair value through profit or loss	641	10,663	-	10,663	
"	Yuanta Wan Tai Money Market Fund	"	"	2,497	38,962	-	38,962	
"	Franklin Templeton Sinoam Money Market Fund	"	"	2,992	31,915	-	31,915	
"	Mega Diamond Money Market Fund	"	"	2,894	37,447	-	37,447	
	Total				118,987		118,987	

Note: If there are public markets prices, the fair value shall be evaluated by the last operating date of the accounting duration.

(iv) Information regarding purchase or sale of securities for the period exceeding 300 million or 20% of the Company's paid-in capital: None.

(v) Information on acquisition of real estate with purchase amount exceeding 300 million or 20% of the Company's paid-in capital:

(In thousands of New Taiwan Dollars)

Name of company	Name of property	Transaction date	Transaction amount	Status of payment	Counterparty	Relationship with the Company	If the Counterparty is a related party, disclose the previous transfer information				References for determining price	Purpose of acquisition and current condition	Others
							Owner	Relationship with the Company	Date of transfer	Amount			
The Company	Factory construction and Engineering (Yilan Science Park)	2020/11/19	877,000	As of March 31, 2024, the price paid \$835,434.	FENG YU UNITED ENGINEERING CO., LTD.	-	N/A	N/A	N/A	N/A	Price negotiation	Operating purpose	None
The Company	Hydropower Fire Engineering Contract (Yilan Science Park)	2020/11/27	176,650	As of March 31, 2024, the price paid \$160,423.	YUNG LONG ELECTRIC EQUIPMENT ENTERPRISE CO., LTD.	-	N/A	N/A	N/A	N/A	Price negotiation	Operating purpose	None
The Company	Contract of clean room construction and procurement of clean room equipment (Yilan Science Park)	2021/10/7 2022/1/18	192,150	As of March 31, 2024, the price paid \$172,528.	MARKETECH INTERNATIONAL CORP.	-	N/A	N/A	N/A	N/A	Price negotiation	Operating purpose	None

(vi) Information regarding receivables from disposal of real estate exceeding 300 million or 20% of the Company's paid-in capital: None.

(vii) Information regarding related-parties purchases and/or sales exceeding 100 million or 20% of the Company's paid-in capital: None.

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

(viii) Information regarding receivables from related-parties exceeding 100 million or 20% of the Company's paid-in capital:

(In thousands of New Taiwan Dollars)

Name of company	Related party	Nature of relationship	Ending balance	Turnover rate	Overdue		Amounts received in subsequent period	Allowance for bad debts
					Amount	Action taken		
The Company	BIOTEQUE MEDICAL PHIL. INC.	Subsidiary	214,854	0.83 %	-	-	8,253	-

Note: The amounts of the transaction and the ending balance had been offset in the consolidated financial statements.

(ix) Information regarding trading in derivative financial instruments: None.

(x) Significant transactions and business relationship between the parent company and its subsidiaries for the three months ended March 31, 2024:

(In thousands of New Taiwan Dollars)

No. (Note 1)	Name of company	Name of counter-party	Nature of relationship (Note 2)	Intercompany transactions			Percentage of the consolidated net revenue or total assets
				Account name	Amount	Trading terms	
0	The Company	BIOTEQUE MEDICAL PHIL. INC.	1	Accounts receivable	112,383	OA 270	2.36%
0	The Company	BIOTEQUE MEDICAL PHIL. INC.	1	Processing costs	10,960	There is no significant difference from translation terms with non-related parties.	2.21%
0	The Company	BIOTEQUE MEDICAL PHIL. INC.	1	Other receivables	102,471		OA 270
0	The Company	BIOTEQUE MEDICAL PHIL. INC.	1	Accounts payable	34,259	OA 60	0.72%
0	The Company	BONTEQ MEDICAL DISTRIBUTION PHIL. INC.	1	Operating revenue	6,998	There is no significant difference from translation terms with non-related parties.	1.41%
0	The Company	BONTEQ MEDICAL DISTRIBUTION PHIL. INC.	1	Accounts receivable	2,006		OA 180
1	BIOTEQUE MEDICAL CO., LTD.	BIOTEQUE MEDICAL PHIL. INC.	3	Other receivables	188	OA 180	-%
1	BIOTEQUE MEDICAL PHIL. INC.	BONTEQ MEDICAL DISTRIBUTION PHIL. INC.	3	Operating revenue	24,371	There is no significant difference from translation terms with non-related parties.	4.91%
1	BIOTEQUE MEDICAL PHIL. INC.	BONTEQ MEDICAL DISTRIBUTION PHIL. INC.	3	Accounts receivable	8,329		OA 120

Note 1: Company numbering as follows:

Parent company—0

Subsidiary starts from 1

Note 2: The numbering of the relationship between transaction parties as follows:

Parent company to subsidiary—1

Subsidiary to parent company—2

Subsidiary to subsidiary—3

Note 3: The amounts of the transaction and the ending balance had been offset in the consolidated financial statements.

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

## (b) Information on investees:

The following are the information on investees for the three months ended March 31, 2024 (excluding information on investees in Mainland China):

(In thousands of New Taiwan Dollars)

Name of investor	Name of investee	Location	Main businesses and products	Original investment amount		Balance as of March 31, 2024			Net income (losses) of investee	Share of profits (losses) of investee	Remark
				March 31, 2024	December 31, 2023	Shares (in thousands)	Percentage of ownership	Carrying value			
The Company	CHUNGTEX INVESTMENT CO., LTD.	Taipei	Investment activities	28,800	28,800	2,880	100 %	30,208	-	-	Subsidiary
The Company	BIOTEQUE MEDICAL PHIL. INC.	Philippines	Manufacturing and Trading of Medical equipment	299,315	299,315	4,481	100 %	491,149	1,119	1,119	"
BIOTEQUE MEDICAL PHIL. INC.	BONTEQ MEDICAL DISTRIBUTION PHIL. INC.	Philippines	Trading of Medical equipment	6,801	6,801	100	100 %	54,030	5,574	5,574	Investment through subsidiary

Note : The amount of the transaction and the ending balance had been offset in the consolidated financial statements.

## (c) Information on investment in mainland China: None.

## (d) Major shareholders:

Shareholder's Name	Shareholding	Shares	Percentage
Ke Yue Co., Ltd.		6,788,000	9.79 %

## (14) Segment information:

There were no significant changes in the Group's segment, as well as the profit and loss measurement basis, as disclosed in the consolidated financial statements for the year ended December 31, 2023.

The Group's operating segment information and reconciliation were as follows:

	For the Three months ended March 31, 2024					
	Segment A	Segment B	Segment C	Other Segment	Reconciliation and elimination	Total
Revenue:						
Revenue from external customers	\$ 174,650	87,378	230,081	4,152	-	496,261
Intersegment revenue	-	5,617	-	-	(5,617)	-
Total revenue	<u>\$ 174,650</u>	<u>92,995</u>	<u>230,081</u>	<u>4,152</u>	<u>(5,617)</u>	<u>496,261</u>
Reporting segment profit or loss	<u>\$ 13,029</u>	<u>16,698</u>	<u>110,570</u>	<u>19,130</u>	<u>-</u>	<u>159,427</u>
	For the three months ended March 31, 2023					
	Segment A	Segment B	Segment C	Other Segment	Reconciliation and elimination	Total
Revenue:						
Revenue from external customers	\$ 161,220	92,775	195,684	6,257	-	455,936
Intersegment revenue	-	6,228	-	-	(6,228)	-
Total revenue	<u>\$ 161,220</u>	<u>99,003</u>	<u>195,684</u>	<u>6,257</u>	<u>(6,228)</u>	<u>455,936</u>
Reporting segment profit or loss	<u>\$ 8,636</u>	<u>19,588</u>	<u>95,355</u>	<u>670</u>	<u>-</u>	<u>124,249</u>

The material reconciling items of the above reportable segment as below:

Total reportable segment revenue should eliminate intersegment revenue by \$5,617 and \$6,228 for the three months ended March 31, 2024 and 2023, respectively.